Combination of chemotherapy and immunotherapy for colon cancer in China: A meta-analysis

Table 1 Clinical information from the eligible trials

Ref.	Age(yr)	Tumor characteristic (TNM)	Regimens(per arm)	Patients (male)	Culture conditions of CIK cells	Culture conditions of DC cells	CIK regimens
Zhang et al[24]	UK	II, III, IV	Chemo	31 (UK)	IFNγ, CD3, IL1, IL-2	GM-CSF,IL-4, TNFα	> 1.0 × 109/course
			Chemo-	32 (UK)
			DC-CIK	Randomized
Zhu et al[25]	58.3 (Mid)	II, III, IV	Chemo	43 (27)	IFNγ, CD3, IL-2	IFNγ, LPS	1.1-8.0 × 1010/course
	59.2 (Mid)		Chemo-	40 (24)
			DC-CIK	Treatment program
Ying et al[23]	UK	II, III	Chemo	51 (25)	IFNγ, CD3, IL-1, IL-2	GM-CSF,IL-4, TNFα	≥ 1010/course
			Chemo-	51 (31)
			DC-CIK	Retrospective analysis
Yuan et al[26]	UK	III, IV	Chemo	21 (16)	IFNγ, CD3, IL-1,IL-2	GM-CSF,IL-4, TNFα,IFNγ	≥ 1010/course
			Chemo-	21 (15)
			DC-CIK	Randomized
Cai et al[20]	44.5 (Ave)46.7 (Ave)	II, III	Chemo	40 (23)	IFNγ, CD3, IL-1,IL-2		UK
			Chemo-	40 (25)
			CIK	Randomized
Wei et al[22]	55.5 (Mid) 54 (Mid)	I, II, III	Chemo	82 (41)	IFNγ, CD3, IL-1,IL-2	GM-CSF,IL-4, TNFα,IFNγ	≥ 1010/course
			Chemo-	41 (18)
			DC-CIK	Retrospective analysis
Li et al[21]	57.5 (Ave)54.5 (Ave)	II, III	Chemo	20 (15)	IFNγ, CD3, IL-2	GM-CSF,IL-4, IFNγ	UK
			Chemo-	20 (13)
			DC-CIK	Randomized

The table summarizes patient information regarding cases, age, details of the immunotherapy including dendritic cell (DC), cytokine-induced killer (CIK) cells or DC-CIK cells, and the culture conditions used for the cells. IFNγ: Interferon-gamma; IL: Interleukin; GM-CSF: Granulocyte-macrophage colony-stimulating factor; TNFα: Tumor necrosis factor-alpha; UK: Unknown; Ave: Average; Mid: Median.